WO2006020269A3 - Biomarkers of neurodegenerative disease - Google Patents

Biomarkers of neurodegenerative disease Download PDF

Info

Publication number
WO2006020269A3
WO2006020269A3 PCT/US2005/025491 US2005025491W WO2006020269A3 WO 2006020269 A3 WO2006020269 A3 WO 2006020269A3 US 2005025491 W US2005025491 W US 2005025491W WO 2006020269 A3 WO2006020269 A3 WO 2006020269A3
Authority
WO
WIPO (PCT)
Prior art keywords
biomarkers
neurodegenerative disease
disclosed
methods
neurodegenerative
Prior art date
Application number
PCT/US2005/025491
Other languages
French (fr)
Other versions
WO2006020269A2 (en
Inventor
Paul D Coleman
Howard J Federoff
Kathleen Maguire-Zeiss
Timothy R Mhyre
Roger M Kurlan
Christopher Cox
Fredrick Marshall
Original Assignee
Univ Rochester
Paul D Coleman
Howard J Federoff
Kathleen Maguire-Zeiss
Timothy R Mhyre
Roger M Kurlan
Christopher Cox
Fredrick Marshall
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rochester, Paul D Coleman, Howard J Federoff, Kathleen Maguire-Zeiss, Timothy R Mhyre, Roger M Kurlan, Christopher Cox, Fredrick Marshall filed Critical Univ Rochester
Priority to CA002574727A priority Critical patent/CA2574727A1/en
Priority to AU2005274788A priority patent/AU2005274788A1/en
Priority to JP2007522634A priority patent/JP2008506415A/en
Priority to EP05795150A priority patent/EP1797425A2/en
Publication of WO2006020269A2 publication Critical patent/WO2006020269A2/en
Publication of WO2006020269A3 publication Critical patent/WO2006020269A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

Disclosed are biomarkers for neurodegenerative diseases. Methods of identifying such biomarkers and methods of using such biomarkers to, for example, diagnose neurodegenerative disease and monitor disease progression and treatment. Assays, kits, and solid supports related to the biomarkers are also disclosed.
PCT/US2005/025491 2004-07-19 2005-07-19 Biomarkers of neurodegenerative disease WO2006020269A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002574727A CA2574727A1 (en) 2004-07-19 2005-07-19 Biomarkers of neurodegenerative disease
AU2005274788A AU2005274788A1 (en) 2004-07-19 2005-07-19 Biomarkers of neurodegenerative disease
JP2007522634A JP2008506415A (en) 2004-07-19 2005-07-19 Biomarkers for neurodegenerative diseases
EP05795150A EP1797425A2 (en) 2004-07-19 2005-07-19 Biomarkers of neurodegenerative disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58931804P 2004-07-19 2004-07-19
US60/589,318 2004-07-19

Publications (2)

Publication Number Publication Date
WO2006020269A2 WO2006020269A2 (en) 2006-02-23
WO2006020269A3 true WO2006020269A3 (en) 2007-04-05

Family

ID=35907991

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/025491 WO2006020269A2 (en) 2004-07-19 2005-07-19 Biomarkers of neurodegenerative disease

Country Status (6)

Country Link
EP (1) EP1797425A2 (en)
JP (1) JP2008506415A (en)
CN (1) CN101137903A (en)
AU (1) AU2005274788A1 (en)
CA (1) CA2574727A1 (en)
WO (1) WO2006020269A2 (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0512401D0 (en) * 2005-06-17 2005-07-27 Randox Lab Ltd Method
US20080260725A1 (en) * 2007-03-29 2008-10-23 Ulhas Naik Tag and target delivery system
DE102007041657A1 (en) * 2007-09-03 2009-03-05 Protagen Ag Marker sequences for multiple sclerosis and their use
SG187453A1 (en) 2008-01-18 2013-02-28 Harvard College Methods of detecting signatures of disease or conditions in bodily fluids
FR2929292A1 (en) 2008-03-28 2009-10-02 Exonhit Therapeutics S A Sa In vitro or ex vivo process, useful e.g. for detecting the presence of Alzheimer's disease or the risk of developing Alzheimer's disease in a mammal, comprises determination of the presence of alteration in one or more genes or RNA
US20110251091A1 (en) 2008-09-12 2011-10-13 Cornell University Thyroid tumors identified
US20100304371A1 (en) * 2009-05-29 2010-12-02 Ana Maria Zarraga Compositions and methods for detecting mycobacteria
CN101961240B (en) * 2009-07-24 2012-05-30 瑞鼎科技股份有限公司 Biosensor, probe, sensing device and biosensor manufacturing method
WO2011087009A1 (en) * 2010-01-14 2011-07-21 学校法人埼玉医科大学 Regulatory gene controlling saccharometabolism, lipid metabolism, obesity and life, protein, and screening method
CA2806304A1 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting prenatal or pregnancy-related diseases or conditions
US20120053073A1 (en) 2010-07-23 2012-03-01 President And Fellows Of Harvard College Methods for Detecting Signatures of Disease or Conditions in Bodily Fluids
CA2806293A1 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
MX2013000917A (en) 2010-07-23 2013-07-05 Harvard College Methods of detecting diseases or conditions using phagocytic cells.
GB201021509D0 (en) * 2010-12-20 2011-02-02 Reactivlab Ltd Assay method
CN102135544A (en) * 2011-02-23 2011-07-27 中国人民解放军第二军医大学 Application of cyclin protein G1
US20120232016A1 (en) * 2011-03-08 2012-09-13 Coleman Paul D Method and system to detect and diagnose alzheimer's disease
AU2012250496A1 (en) * 2011-05-03 2013-11-28 Commonwealth Scientific And Industrial Research Organisation Method for detection of a neurological disease
US20150099645A1 (en) * 2012-03-14 2015-04-09 Stephen Marx Means and methods for diagnostics and therapeutics of diseases
CN102707065A (en) * 2012-03-23 2012-10-03 常熟市虞山绿茶有限公司 Application of Prohibitin protein antibody to preparing kit for diagnosing senile dementia
AU2013266086B2 (en) * 2012-05-25 2018-03-01 Berg Llc Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-beta
CA2876711A1 (en) 2012-06-15 2013-12-19 Harry Stylli Methods of detecting diseases or conditions using circulating diseased cells
US20140179805A1 (en) 2012-06-15 2014-06-26 Harry Stylli Methods of detecting diseases or conditions
GB201212084D0 (en) * 2012-07-06 2012-08-22 Randox Lab Ltd Tropomyosin isoforms related to alzheimers disease and mild cognitive impairment
US11585814B2 (en) 2013-03-09 2023-02-21 Immunis.Ai, Inc. Methods of detecting prostate cancer
EP2965077B1 (en) 2013-03-09 2022-07-13 Harry Stylli Methods of detecting cancer
US9588129B2 (en) * 2013-03-15 2017-03-07 Amira Medical Technologies Inc. Methods for analyzing blood to detect diseases associated with abnormal protein aggregation
KR101497797B1 (en) * 2013-03-19 2015-03-04 이화여자대학교 산학협력단 Screening method for the agents for treating Parkinson's Disease by monitoring Heat shock protein and LRPPRC signaling
CA2920474C (en) 2013-07-11 2021-05-04 University Of North Texas Health Science Center At Fort Worth Blood-based screen for detecting neurological diseases in primary care settings
CN103487587B (en) * 2013-09-16 2017-02-01 承功（厦门）生物科技有限公司 Detection board and detection kit for in vitro detection of Alzheimer Disease
WO2015081166A1 (en) 2013-11-26 2015-06-04 University Of North Texas Health Science Center At Fort Worth Personalized medicine approach for treating cognitive loss
US10023864B2 (en) 2014-06-06 2018-07-17 Berg Llc Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-beta
AU2015314813B2 (en) 2014-09-11 2022-02-24 Immunis.Ai, Inc. Methods of detecting prostate cancer
US10282875B2 (en) 2015-12-11 2019-05-07 International Business Machines Corporation Graph-based analysis for bio-signal event sensing
CN105548574A (en) * 2016-02-02 2016-05-04 潍坊三维生物工程集团有限公司 Kit and method for detecting content of C1 inhibitor and application
WO2017193115A1 (en) * 2016-05-06 2017-11-09 Nanosomix, Inc. Synaptic protein biomarkers and differential diagnosis of alzheimer's disease and other neurodegenerative disorders
US10391079B2 (en) 2016-07-26 2019-08-27 Ausio Pharmaceuticals, Llc Methods of diagnosing and treating Alzheimer's disease with S-equol
US10914748B2 (en) 2016-09-08 2021-02-09 UNIVERSITé LAVAL Erythrocyte-derived extracellular vesicles as a biomarker for clinically assessing Parkinson's disease
EP3312611B1 (en) * 2016-10-21 2020-02-26 Dr. Power Stem Biomedical Research Inc., Ltd. Method for diagnosis of alzheimer's disease
US11193933B2 (en) * 2016-10-26 2021-12-07 Dr. Power Stem Biomedical Research Inc., Ltd. Measuring GAPDH protein for diagnosis and treatment of alzheimer's disease
TWI622771B (en) * 2016-10-27 2018-05-01 百威研發股份有限公司 Method for diagnosis of alzheimer's disease
WO2018081878A1 (en) * 2016-11-07 2018-05-11 Macquarie University Modulation of protein accumulation and uses therefor
US10345302B2 (en) * 2017-02-19 2019-07-09 Sheng-He Huang Circulating astrocytes and MFSD2A as biomarkers
US10837970B2 (en) 2017-09-01 2020-11-17 Venn Biosciences Corporation Identification and use of glycopeptides as biomarkers for diagnosis and treatment monitoring
CN114828897A (en) * 2019-10-21 2022-07-29 麦考瑞大学 Modulation of cell viability
CN113801929A (en) * 2020-06-11 2021-12-17 香港科技大学 Method for identifying a drug capable of treating alzheimer's disease
CN111986730A (en) * 2020-07-27 2020-11-24 中国科学院计算技术研究所苏州智能计算产业技术研究院 Method for predicting siRNA silencing efficiency
WO2023049830A1 (en) * 2021-09-24 2023-03-30 Wake Forest University Health Sciences Detecting and treating conditions associated with neuronal senescence

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CARONTI B ET AL: "Dopamine transporter immunoreactivity in peripheral blood lymphocytes in Parkinson's disease", JOURNAL OF NEURAL TRANSMISSION, vol. 108, no. 7, 2001, pages 803 - 807, XP002383729, ISSN: 0300-9564 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 2001, KVETNOY I M ET AL: "Diagnostic value of immunocytochemical identification of tau-protein in human peripheral blood lymphocytes in Alzheimer's disease", XP002383727, Database accession no. PREV200200142139 *
GIUBILEI F ET AL: "INTERACTION BETWEEN CHOLINERGIC AND CATECHOLAMINERGIC SYSTEMS IN NEURODEGENERATIVE COGNITIVE IMPAIRMENT.", SOCIETY FOR NEUROSCIENCE ABSTRACT VIEWER AND ITINERARY PLANNER, vol. 2002, 2002, & 32ND ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE; ORLANDO, FLORIDA, USA; NOVEMBER 02-07, 2002, pages Abstract No. 786.15 URL - http://sf, XP002383732 *
IMMUNOLOGIYA, no. 2, 2001, pages 46 - 48, XP009067325, ISSN: 0206-4952 *
INESTROSA N C ET AL: "Blood markers in Alzheimer disease: Subnormal acetylcholinesterase and butyrylcholinesterase in lymphocytes and erythrocytes", JOURNAL OF THE NEUROLOGICAL SCIENCES, vol. 122, no. 1, 1994, pages 1 - 5, XP002383730, ISSN: 0022-510X *
KVETNOY I M ET AL: "Diffuse neuroendocrine system and mitochondrial diseases: Molecular and cellular bases of pathogenesis, new approaches to diagnosis and therapy", NEUROENDOCRINOLOGY LETTERS 2000 SWEDEN, vol. 21, no. 2, 2000, pages 83 - 99, XP009067319, ISSN: 0172-780X *
LEVITE M ET AL: "Dopamine interacts directly with its D3 and D2 receptors on normal human T cells, and activates beta1 integrin function", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 31, no. 12, December 2001 (2001-12-01), pages 3504 - 3512, XP002383728, ISSN: 0014-2980 *
SCHIPPER H M ET AL: "EVALUATION OF HEME OXYGENASE-1 AS A SYSTEMIC BIOLOGICAL MARKER OF SPORADIC AD", NEUROLOGY, LIPPINCOTT WILLIAMS & WILKINS, PHILADELPHIA, US, vol. 6, no. 54, 28 March 2000 (2000-03-28), pages 1297 - 1304, XP001064649, ISSN: 0028-3878 *
TSUJI T ET AL: "Proteomic profiling and neurodegeneration in Alzheimer's disease.", NEUROCHEMICAL RESEARCH, vol. 27, no. 10, October 2002 (2002-10-01), pages 1245 - 1253, XP002383733, ISSN: 0364-3190 *

Also Published As

Publication number Publication date
CN101137903A (en) 2008-03-05
WO2006020269A2 (en) 2006-02-23
EP1797425A2 (en) 2007-06-20
JP2008506415A (en) 2008-03-06
AU2005274788A1 (en) 2006-02-23
CA2574727A1 (en) 2006-02-23

Similar Documents

Publication Publication Date Title
WO2006020269A3 (en) Biomarkers of neurodegenerative disease
WO2007011907A3 (en) Alpha-synuclein antibodies and methods related thereto
WO2007047408A3 (en) Promac signature application
WO2005114190A3 (en) Methods of identifying biomarkers
WO2007019376A3 (en) Methods and compositions for diagnosis of iga-and igm-mediated kidney diseases
WO2007007173A3 (en) Human anti-madcam antibodies
DE602007011566D1 (en) Ankheit
WO2004071517A3 (en) Uses of il-23 related reagents
WO2005107491A3 (en) Multi-lectin affinity chromatography and uses thereof
WO2006059252A3 (en) Methods and fluorinated compositions for treating amyloid-related diseases
WO2006053315A3 (en) Methods and compositions for treating cellular proliferative diseases
WO2005113831A3 (en) Biomarkers for multiple sclerosis and methods of use thereof
WO2006138219A3 (en) Methods of diagnosis / prognosis of inflammatory conditions
WO2007056435A3 (en) Dynamin mediated diseases and associated methods and products
WO2006085121A3 (en) Vgp peptide fragments as biomarkers for schizophrenic and bipolar disorders
WO2006099543A3 (en) Methods for assessing antibody-mediated cytotoxicity
WO2007038264A3 (en) Gapr-1 methods
WO2006091861A8 (en) Compositions and methods relating to cns lymphoma
WO2008067559A3 (en) Methods for treating and diagnosing fibrotic and fibroproliferative diseases
WO2007071874A3 (en) Novel compounds which interact with pea-15
EP1901066A4 (en) Method of diagnosing alzheimer s disease using serum glycoprotein as biomarker
WO2005034737A3 (en) Methods for diagnosing and treating endoplasmic reticulum (er) stress diseases
WO2007120955A3 (en) Genes affecting human memory performance
WO2004045376A3 (en) Screening methods to identify treatments for autoimmune disease
WO2006108051A3 (en) Compositions and methods relating to alzheimer's disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2007522634

Country of ref document: JP

Ref document number: 2574727

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005274788

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005795150

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005274788

Country of ref document: AU

Date of ref document: 20050719

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005274788

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200580031406.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 2005795150

Country of ref document: EP